TT4CL (Targeted treatment for cutaneous leishmaniasis) is a new Horizon 2020-funded project which aims to reduce the burden of Neglected Infectious Diseases (NID) and its social and economic impacts. Horizon 2020, the European Union’s (EU) research and innovation programme, helps to bridge the gap between preclinical and clinical development and thus helps to advance promising new drug candidates along the development pipeline. The TT4CL consortium, which brings together partners from academia and industry in Europe and disease-endemic countries, has been awarded EUR3.75 million to develop an oral treatment, D121, against one of the most neglected tropical diseases, cutaneous leishmaniasis.
July 16, 2019
Avivia B.V. is pleased to announce the expansion of its Business Development activities by the appointment of Marcel Langoor, PhD.
April 3, 2019
Marleen De Vriese and Hans Platteeuw are attending this weeks’ biannual meeting on Buruli Ulcer and Skin NTD’s at the WHO headquarters in Geneva (Switzerland).
March 25, 2019
The DDF Summit brings together leading formulation development, drug delivery and device development professionals from both industry and academia to share and discuss their latest work. Avivia will also be present there! Don't hesitate to arrange a meeting in advance by sending us a message or giving us a call!
February 14, 2019
The Netherlands Antibiotic Development Platform (NADP) facilitates the collaboration between public and private organisations, to enhance the development of new antibiotics and alternative therapies for infectious diseases in humans and animals.
NADP will identify relevant research groups, institutes and companies involved in chemical, biological, and/or biomedical antibiotic research to forge collaborations through targeted connections and will organise regular meetings with interested parties. At a later stage, the NADP will provide Intellectual Property Vouchers, Value Proposition Vouchers and Lead Development Vouchers.
May 1, 2018
Avivia/Excipia will be present as exhibitor on the 7th annual conference on pharmaceutical excipients.
The event will be organized by IPEC Europe and APV on 18-19 September 2018 in Cologne, Germany
The conference will focus on “hot topics” in the area of excipient regulation and technology.
During the conference and workshops topics like contamination in excipients, requirements for excipients, implementation of GMP in an excipient manufacturing site, supplier qualification and auditing, analytical data and certificates of analysis provided by suppliers of excipients will be discussed.
April 3, 2018
The world over, members of the Reproductive Health Supplies Coalition work tirelessly to broaden access to a range of affordable, quality contraceptives. In March, we will gather in Brussels to share our successes and, in particular, to celebrate the advances towards supply security in francophone Africa. This region boasts some of the world’s greatest reproductive health successes but also some of the most troubling statistics and seemingly intractable challenges.
As a new member of this coalition, Avivia is committed to making a valuable contribution.
February 20, 2018
From big pharma, through the smaller biotechnology companies all the way to university research teams and spin outs. The DDF Summit brings the most interesting studies and exciting technologies to you.
Avivia will participate at this event, so if you would like to meet us there, please get in touch!
February 20, 2018
Professor Dr. P.H. Nibbering from the Department of Infectious Diseases - UMC Leiden (LUMC) has received an NWO grant entitled: Next stage development of the novel synthetic antimicrobial peptide SAAP-148 (NESDAP).
The project focuses on the development of a synthetic peptide for topical wound treatment, in response to growing concern for untreatable infections, due to antimicrobial resistance.
Together with LUMC and other project partners involved, Avivia will perform several parallel development tests, using nanoparticles and PLGA microspheres, to optimize the delivery of SAAP-148 deep into wounds with a controlled release over time.
December 19, 2017
London dec 2017
In the past 10 years, Avivia has been involved in the pharmaceutical application of mesoporous silica in a diverse range of functionalities in pharmaceutical formulations, ranging from its "simple" application as a processing aid, to the more advanced applications in solubility, stability and bioavailability improvement and most recently the construction of stable ternary amorphous systems.
December 19, 2017
M-building – Novio Tech Campus
6534 AT Nijmegen, The Netherlands
Email info [at] avivia.nl
Phone - Reception +31 (0)6-1968-6732